News Search Results
Feb 04, 2026, 08:00 ET Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
pharmaceutical and agricultural industries, and Shanghai Lishan Biopharmaceuticals Co., Ltd. ("Lishan Biotech"), a China-based clinical-stage biotechnology company focused on innovative therapies in the fields of immunity and inflammation, today announced that Biomica Ltd. ("Biomica"), Evogene's subsidiary
More news about: Evogene; Shanghai Lishan Biopharmaceuticals Co., Ltd.
Feb 04, 2026, 08:00 ET Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial
BRISBANE, Australia , Feb. 4, 2026 /PRNewswire/ - Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant
More news about: Providence Therapeutics Holdings Inc
Feb 04, 2026, 08:00 ET MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
CAMBRIDGE, Mass., Feb. 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an artificial
More news about: MetaVia Inc.
Feb 04, 2026, 08:00 ET Stevenson Search Partners Announces Amelia Tyagi as Inaugural Advisory Board Member
more than 40 years of experience, Stevenson Search Partners is a trusted executive search and total talent solutions advisor servicing the global biotechnology, pharmaceutical, medical technology, health technology and CRO/CDMO sectors, with offices in the U.S. and the U.K. Dedicated to finding executive
More news about: Stevenson Search Partners
Feb 04, 2026, 07:00 ET Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis
More news about: Kodiak Sciences Inc.
Feb 04, 2026, 07:00 ET Nuveen's Sixth Annual EQuilibrium Global Institutional Investor Survey: Institutional Investors Identify AI, Energy Transition and Deglobalization as Key Megatrends Reshaping Investment Strategy
private equity, cryptocurrency/blockchain/digital assets, energy (renewables, semiconductors, utilities), cybersecurity and healthcare (biotechnology, pharmaceuticals, life sciences).While 74% of respondents agree that 2025 delivered more upside than downside to portfolios, nearly half
More news about: Nuveen
Feb 04, 2026, 06:45 ET Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 04, 2026, 06:30 ET Bio-Techne Declares Dividend
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency
More news about: Bio-Techne Corporation
Feb 04, 2026, 06:30 ET Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of additional
More news about: Immunic, Inc.
Feb 04, 2026, 06:30 ET Bio-Techne Releases Second Quarter Fiscal 2026 Results
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and
More news about: Bio-Techne Corporation
Feb 04, 2026, 06:00 ET Goddess Maintenance Co. Expands Its BioTech Blowout™ Offering With the Launch of Shampoo and Conditioner
science-driven brand delivering high-performance hair care. Designed for everyone and informed by the professional salon world, it merges advanced biotechnology with streamlined performance to support hair health from the inside out.At the heart of the new launches is the BIOPROTECTION™ System, designed
More news about: Goddess Maintenance Co.
Feb 04, 2026, 04:52 ET Lupin Receives Highest ESG Rating from CDP for Climate Change and Water Security
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Feb 03, 2026, 16:30 ET Strong 2H and Full Year 2025 Results Driven by Leading Technology, Disciplined Execution
commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) effect of changes in agricultural and related policies
More news about: Corteva Agriscience
Feb 03, 2026, 16:01 ET AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 03, 2026, 11:35 ET Three Rubin Rudman Partners Named to 2026 Lawdragon 500 Leading Environmental Lawyers - The Green 500
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Feb 03, 2026, 11:00 ET Fernando Miquelarena Joins Michroma as Independent Board Director
SAN FRANCISCO, Feb. 3, 2026 /PRNewswire/ -- Michroma, a biotechnology company developing high-performance, scalable natural food colorants through precision fermentation, today announced that Fernando Miquelarena has joined
More news about: Michroma
Feb 03, 2026, 09:00 ET Slingshot Biosciences Announces Rapid Expansion into the United Kingdom and European Union Markets
programs. The company's aggressive growth continues, driven by the broad adoption of its cell-mimic technology by hundreds of pharmaceutical companies, biotechnology firms, contract research organizations (CROs), clinical diagnostics laboratories, and academic medical centers worldwide.
More news about: Slingshot Biosciences
Feb 03, 2026, 09:00 ET Slingshot Biosciences Announces Rapid Expansion into the United Kingdom and European Union Markets
programs. The company's aggressive growth continues, driven by the broad adoption of its cell-mimic technology by hundreds of pharmaceutical companies, biotechnology firms, contract research organizations (CROs), clinical diagnostics laboratories, and academic medical centers worldwide.
More news about: Slingshot Biosciences
Feb 03, 2026, 09:00 ET Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
Feb. 3, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group ("Menarini") as an additional milestone payment, following the completion
More news about: Insilico Medicine
Feb 03, 2026, 09:00 ET Connecticut Innovations to Host Second Annual Talent Fair in New Haven
scale and succeed here in Connecticut."The fair will feature two separate industry networking sessions, with the morning session focused on biotechnology, life sciences and healthcare, followed by afternoon sessions on climate, consumer and technology. Students attending the fair will have direct
More news about: Connecticut Innovations
Feb 03, 2026, 09:00 ET HighVista Closes Oversubscribed Private Equity Fund XI at $800 Million, Surpassing Target
span private markets, including private credit, lower middle market private equity, and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-asset alternatives.Important Disclosure The views and options
More news about: HighVista Strategies LLC
Feb 03, 2026, 08:54 ET Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Strategic Advisory Board
life sciences, and biotechnology organizations on strategy, governance, capital formation, and enterprise transformation. During his tenure at EY, he served as Americas Health Sciences Leader and was one of the firm's senior client service partners shaping strategy across pharmaceuticals, biotechnology, healthcare
More news about: Immorta Bio Inc.
Feb 03, 2026, 08:53 ET Ecovia Bio Closes Series B Funding Round Led by Pointe Angels to Expand Manufacturing Capacity
significant value for our investors while strengthening Michigan's position as a leader in biotechnology and advanced manufacturing."About Ecovia BioEcovia Bio is a Michigan-based biotechnology company, a spinout from the University of Michigan, focused on the development and commercialization
More news about: Ecovia Bio
Feb 03, 2026, 08:05 ET Rigel Appoints Michael P. Miller to the Board of Directors
appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries."Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board,"
More news about: Rigel Pharmaceuticals, Inc.
Feb 03, 2026, 08:00 ET ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
BOSTON, Feb. 3, 2026 /PRNewswire/ -- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage
More news about: ZipBio